Sign in Create account
Sign in and upgrade to a paid plan to export corporate actions as CSV.
Sign in and upgrade to a paid plan to export futures history as CSV.
Sign in and upgrade to a paid plan to export futures history as CSV.

Unichem Laboratories Limited

Healthcare · Pharmaceuticals & Biotechnology

NSE: UNICHEMLAB BSE: 506690
₹545.50
▼ -22.90 (-4.03%)
Sept. 30, 2026 · NSE · nse_bhavcopy
Quality
62/100
Moderate
Valuation
77/100
Undervalued
Momentum
84/100
Bullish

QVM read Cheap and turning up Quality Moderate, Valuation Undervalued, Momentum Bullish

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

About

Unichem Laboratories is an Indian pharmaceutical company, headquartered in Mumbai. It manufactures and markets pharmaceutical formulations across the globe, including the regulated markets of the USA and Europe.

Source: Wikipedia

Key Metrics

Market Capitalization
₹3,841 Cr
PE (TTM)
23.1
Industry median 36.1 (152 companies)
Price to Book
1.4
PEG (TTM)
1.2
Institutions holding %
11.36%
FII + DII, latest filed period
Piotroski Score
6
Relative return vs Nifty50, qtr %
21.0
Relative return vs Sector, qtr %
15.0
Free Cash Flow
₹-119 Cr
as of March 31, 2026
Industry median ₹-0 Cr (198 companies)
EPS Growth (YoY)
403.85%
as of June 30, 2026
Industry median 26.14% (180 companies)
Net Profit Growth (TTM)
2.06%
as of June 30, 2026
Industry median 6.21% (175 companies)
Operating Revenue Growth (TTM)
-19.41%
as of June 30, 2026
Industry median 9.08% (175 companies)
Profit Growth (YoY)
-130.05%
as of March 31, 2026
Industry median 22.20% (176 companies)
Revenue Growth (YoY)
-4.68%
as of June 30, 2026
Industry median 14.05% (173 companies)
Current Ratio
2.48
as of March 31, 2026
Industry median 1.84 (197 companies)
Debt to Equity
0.17
as of March 31, 2026
Industry median 0.14 (186 companies)
Interest Coverage
20.59
as of June 30, 2026
Industry median 10.58 (182 companies)
Net Margin
1.51%
as of June 30, 2026
Industry median 9.35% (179 companies)
Operating Margin (EBIT)
2.37%
as of June 30, 2026
Industry median 14.22% (181 companies)
Operating Margin (TTM)
16.48%
as of June 30, 2026
Industry median 12.41% (182 companies)
Return on Assets
6.77%
as of March 31, 2026
Industry median 5.54% (180 companies)
Return on Capital Employed
11.36%
as of March 31, 2026
Industry median 12.43% (181 companies)
Return on Equity
9.30%
as of March 31, 2026
Industry median 9.66% (179 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

2 of 7 met
  • No Revenue is higher than a year earlier in each of the last 4 quarters
  • No Quality score is Strong (70 or more)
  • No Piotroski F-score is 7 or more (score 6)
  • Yes Debt to equity is below 0.5 (0.17)
  • No Return on equity is 15% or more (9.3%)
  • Yes Net cash flow for the latest year is positive
  • No Cash from operations is higher than the year before

Ownership

2 of 3 met
  • No FII/FPI or DII holding rose in the latest quarter
  • Yes Promoter holding rose or was unchanged in the latest quarter
  • Yes Promoter pledge is 5% of their holding or less and not rising (0.0% pledged)

Peer comparison

1 of 3 met
  • Yes 1-year return beats the industry median
  • No Revenue growth beats the industry median
  • No Profit growth beats the industry median

Value and momentum

4 of 6 met
  • Yes Price sits in the Buy zone of its own historical PE range (Buy Zone)
  • Yes Valuation score is Undervalued (70 or more)
  • Yes Momentum score is Bullish (70 or more)
  • No Price is above the 5, 10 and 20 day averages
  • Yes Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs NIFTY 50)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
-4.0%
Low 542.1000 · High 579.2000
1W return
-4.8%
Low 526.6000 · High 608.0000
1M return
-2.0%
Low 497.8000 · High 608.0000
52W return
13.1%
Low 278.2000 · High 687.2000
Lifetime High ₹899.6500 (Nov. 8, 2024)
Lifetime Low ₹77.7000 (Feb. 10, 1998)

Full price history and technicals →

Technicals

Full technicals, indicators & Volume/Delivery →

EMA & SMA

Bullish3
Bearish3
5D
550.8
10D
548.8
20D
545.8
50D
531.8
100D
500.2
200D
433.2

Delivery and volume

Day avg. delivery
37.7%
Week avg. delivery
10.9%
Month avg. delivery
18.3%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

555.60
Pivot
First resistance569.10
Second resistance592.70
Third resistance606.20
First support532.00
Second support518.50
Third support494.90
Day RSI50.5
Day MFI84.7
Day MACD4.19
Day MACD signal3.85

Beta

1M2.48
3M-0.62
1Y0.75
3Y0.70

Price change analysis

↓ -2.0%
Over 1 Month
LowHigh
497.80608.00
↑ 15.0%
Over 3 Months
LowHigh
454.05687.20
↑ 82.9%
Over 6 Months
LowHigh
291.30687.20
↑ 13.1%
Over 1 Year
LowHigh
278.20687.20
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →
Current PE 23.1 (own history: 13.0–241.1)
Buy Zone

Financials

View full financials, peers & valuation multiples →
Revenue (June 30, 2026)
₹366 Cr
Net profit (June 30, 2026)
₹6 Cr
Basic EPS (June 30, 2026)
₹0.7900

Ranks #66 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Jun 2026
  • Promoter70.22%
  • Mutual funds9.32%
  • FII/FPI0.90%
  • Other DII1.14%
  • Public18.42%

Largest holders

NameCategoryShares %Shares
Ipca Laboratories LimitedPromoter52.6700%37081011
Dr. Prakash Amrut ModyPromoter12.7800%8997952
Hdfc Small Cap FundPublic7.7500%5458645
Anita Prakash ModyPromoter1.8800%1323400
Dsp Healthcare FundPublic1.5600%1100697

As of June 30, 2026. Only holders the filing discloses individually.

Historical promoter holding

Promoters holdings were unchanged at 70.22% in Jun 2026 qtr

Historical fii holding

FII/FPI holdings decreased from 1.00% to 0.90% in Jun 2026 qtr

Historical mutual fund holding

Mutual funds holdings increased from 9.07% to 9.32% in Jun 2026 qtr

2 mutual fund schemes also hold this stock.

All shareholding details →

Insider trading, SAST & pledges

All 49 insider trades, 12 SAST, 0 pledge events →

Latest insider trades

FiledPersonCategoryTypeQuantityValue
10 Oct 2023 JATIN RAMANLAL MEHTA Employee / designated person Sell 0 ₹0
10 Oct 2023 RAJARAM PAI Other Sell 0 ₹0
10 Oct 2023 GERARD MAJELLA COLE Other Sell 0 ₹0
10 Oct 2023 RAJARAM PAI Other Sell 0 ₹0
10 Oct 2023 GERARD MAJELLA COLE Other Sell 0 ₹0
10 Oct 2023 JATIN RAMANLAL MEHTA Employee / designated person Sell 0 ₹0
22 Sep 2023 IPCA LABORATORIES LIMITED Promoter Buy 0 ₹0
24 Aug 2023 VANDANA PANDEY Employee / designated person Sell 0 ₹0
23 Aug 2023 Dilip Janardan Kunkolienkar Director Sell 0 ₹0
21 Aug 2023 Dilip Janardan Kunkolienkar Director Sell 0 ₹0

All insider and SAST disclosures →

Deals (Bulk & Block)

All 7 deals, with filters and CSV →
DateClientDealActionQuantityPriceExchange
2 Aug 2023 PRAKASH AMRUT MODY Block Sell 23,501,440 402.2500 NSE
2 Aug 2023 IPCA LABORATORIES LIMITED Block Buy 23,501,440 402.2500 NSE
14 Feb 2018 SMC GLOBAL SECURITIES LTD. Bulk Sell 520,060 379.4100 NSE
14 Feb 2018 SMC GLOBAL SECURITIES LTD. Bulk Buy 395,005 379.5200 NSE
14 Feb 2018 NORDEA 1 SICAV INDIAN EQUITY FUND N2239LUA Bulk Sell 540,562 379.2600 NSE
18 Mar 2014 ANITA PRAKASH MODY Bulk Sell 955,000 213.3800 BSE
18 Mar 2014 PRAKASH AMRUT MODY Bulk Buy 955,000 213.3800 BSE

All bulk and block deals →

Board Meetings

View board meeting history →

Quarterly results, AGMs, buybacks and other board-approved business.

DatePurposeResults
11 Aug 2026 Financial Results Yes
5 Feb 2026 Financial Results Yes
11 Nov 2025 Financial Results Yes
4 Aug 2025 Financial Results Yes
22 May 2025 Financial Results Yes

Corporate Announcements

All 2 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
19 Sep 2026 Company Update Unichem Laboratories Ltd - 506690 - Disclosure Under Regulation 30 Of SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015
11 Sep 2026 Company Update Unichem Laboratories Ltd - 506690 - Extension Of The Exercise Period For The Options Granted And Vested Under Unichem Employee Stock Option Scheme 2018

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • Low financial leverage (Debt/Equity 0.17)
  • Comfortable interest coverage (20.6x)
  • Healthy liquidity (Current Ratio 2.48)

Weaknesses

  • Low Return on Equity (9.3%)
  • Thin net profit margin (1.5%)
  • Declining revenue YoY (-4.7%)
  • Declining profit YoY (-130.0%)

Opportunities

Data unavailable.

Threats

Data unavailable.

Board of directors and corporate information →

F&O

View F&O, Options & Backtest →

Data unavailable (no single-stock futures or options activity on record for this company).

Frequently asked questions about Unichem Laboratories Limited

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.